Wedbush reiterates Protagonist Therapeutics stock rating on oral focus
Wedbush reiterated an Outperform rating and $173 price target for Protagonist Therapeutics (PTGX) after its Q3 2026 update. The stock has gained 66% in the past year. The company reported positive Phase 1 data for PN-477 and plans to prioritize its oral formulation. PTGX has $834.6 million in cash and expects a runway through at least 2028. Multiple analysts have raised price targets following FDA approvals of Mimrylo and Icotyde.
How this was made
The 30-second read
Why it matters
The new Phase 1 data and analyst upgrades could trigger a short‑term rally, but long‑term performance hinges on later‑stage trial success.
Market read
Positive trial data and upgraded price targets provide a fresh catalyst for PTGX, likely prompting buying interest.
What to watch
Potential regulatory delays and the need for successful oral formulation trials could temper upside.
Background
Protagonist Therapeutics (PTGX) is a mid‑cap biotech focused on peptide therapeutics for obesity and related conditions. Recent FDA approvals of its drugs have boosted confidence.
Ticker impact
Wedbush reiterated an Outperform rating and raised the price target to $173 after Protagonist Therapeutics reported positive Phase 1 data for its subcutaneous PN-477 formulation and announced upcoming oral trials.
potential upside as investors price in the favorable trial results and upgraded targets
The article provides the first public disclosure of the Phase 1 data and new price targets, which are material for a biotech stock.
Market effects
Strengthens the obesity‑treatment pipeline narrative, may lift peer biotech valuations.
US biotech sector could see modest gains as investors digest the data.
Limited to biotech investors; no broad market effect.
Counterpoint
Phase 1 data are early; execution risk remains high and the market may have already priced in optimism.
Key entities
- AnalystWedbush
Reiterated Outperform rating and raised price target to $173.
- AnalystUBS
Maintained Buy rating citing Mimrylo launch.
